Circle Pharma Stock
Developer of next-generation macrocycle therapies designed to be cell-permeable and deliverable through multiple routes, including oral administration. The company combines structure-based drug design with advanced synthetic chemistry to create therapeutics targeting intracellular protein-protein interactions, addressing unmet clinical needs in cancer.
Founded: 2012
For more Circle Pharma stock information, or to buy or sell private shares, sign up for a MicroVentures account.
Circle Pharma Company Overview
null
Management Team
| David J. Earp, J.D., Ph.D. President & Chief Executive Officer |
| Edward Garmey, M.D. Chief Medical Officer |
